The Effect of Semaglutide on the Intestinal Flora in Obesity

Inclusion Criteria: * 18 to 60 years old; * BMI ≥ 30kg/m²; * At least one self-reported history of unsuccessful lifestyle weight loss; * Subjects who agree to participate in the project and sign the informed consent form. Exclusion Criteria: * Weight changes within 3 months prior to screening (self-reported) \>5%; * Having received any drug treatment for obesity within the three months prior to screening; * The application of hypoglycemic drugs within 3 months before screening, or HbA1c≥ 6.5%, or a history of type 1 or type 2 diabetes; * Participants who have received treatment with immunosuppressants, steroids, antidiarrheal drugs, antibiotics, probiotics, lipid-lowering drugs and/or other gastrointestinal motility drugs within 3 months prior to screening; * Previously diagnosed overweight or obesity due to endocrine causes, such as Cushing's syndrome, etc; * Triglycerides ≥500mg/dL (5.65mmol/L) during screening; * It is known that there are clinically significant gastric emptying abnormalities (e.g., severe diabetic gastroparesis or gastric outlet obstruction), a history of gastrointestinal diseases and surgical history; * Abnormal thyroid function; * History of mental illness; * History of multiple endocrine tumors or medullary thyroid cancer, family history, or calcitonin ≥6pg/mL; * Abnormal liver function during screening, that is, alanine aminotransferase and/or aspartate aminotransferase \> 3\*ULN; * Abnormal renal function during screening, that is, the estimated glomerular filtration rate is less than 60mL/min/1.75m2; * History of cardiovascular diseases; * History of malignant tumors; * Pregnancy or lactation; * As determined by the researcher, there are other physical, psychological or other conditions that make one unsuitable to participate in the trial.